David F. Ackart

1.5k total citations
31 papers, 1.1k citations indexed

About

David F. Ackart is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, David F. Ackart has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Infectious Diseases, 17 papers in Epidemiology and 7 papers in Surgery. Recurrent topics in David F. Ackart's work include Tuberculosis Research and Epidemiology (23 papers), Mycobacterium research and diagnosis (15 papers) and Antibiotic Resistance in Bacteria (7 papers). David F. Ackart is often cited by papers focused on Tuberculosis Research and Epidemiology (23 papers), Mycobacterium research and diagnosis (15 papers) and Antibiotic Resistance in Bacteria (7 papers). David F. Ackart collaborates with scholars based in United States, Switzerland and Haiti. David F. Ackart's co-authors include Randall J. Basaraba, Ian M. Orme, Brendan K. Podell, Crystal A. Shanley, Natalie M. Kirk, Scott T. Nolan, Frank Wolschendorf, Tej B. Shrestha, Michael Niederweis and Stefan H. Bossmann and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Angewandte Chemie International Edition and SHILAP Revista de lepidopterología.

In The Last Decade

David F. Ackart

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David F. Ackart United States 16 634 502 275 188 141 31 1.1k
Rajiv L. Gaur United States 21 449 0.7× 408 0.8× 309 1.1× 184 1.0× 42 0.3× 27 1.3k
Santosh Kumar India 21 412 0.6× 336 0.7× 414 1.5× 221 1.2× 73 0.5× 89 1.4k
Julia Roberts United States 13 335 0.5× 236 0.5× 270 1.0× 63 0.3× 102 0.7× 20 719
Marie I. Samanovic United States 17 469 0.7× 247 0.5× 346 1.3× 47 0.3× 126 0.9× 31 1.1k
Mark J. Koenigsknecht United States 14 823 1.3× 306 0.6× 1.3k 4.8× 211 1.1× 81 0.6× 21 1.9k
Zhongji Meng China 24 342 0.5× 1.3k 2.6× 534 1.9× 143 0.8× 182 1.3× 77 2.4k
Hua Gao China 22 180 0.3× 314 0.6× 602 2.2× 73 0.4× 99 0.7× 42 1.5k
Josephine Ni United States 8 307 0.5× 370 0.7× 1.0k 3.7× 228 1.2× 113 0.8× 14 1.6k
John Adamson South Africa 22 853 1.3× 613 1.2× 585 2.1× 135 0.7× 23 0.2× 34 1.5k
A Wildfeuer Germany 21 458 0.7× 551 1.1× 242 0.9× 78 0.4× 29 0.2× 108 1.6k

Countries citing papers authored by David F. Ackart

Since Specialization
Citations

This map shows the geographic impact of David F. Ackart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David F. Ackart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David F. Ackart more than expected).

Fields of papers citing papers by David F. Ackart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David F. Ackart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David F. Ackart. The network helps show where David F. Ackart may publish in the future.

Co-authorship network of co-authors of David F. Ackart

This figure shows the co-authorship network connecting the top 25 collaborators of David F. Ackart. A scholar is included among the top collaborators of David F. Ackart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David F. Ackart. David F. Ackart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ackart, David F., et al.. (2024). An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis. Vaccine. 42(22). 125909–125909. 7 indexed citations
2.
Ackart, David F., et al.. (2024). Heterogeneity in immune cell composition is associated with Mycobacterium tuberculosis replication at the granuloma level. Frontiers in Immunology. 15. 1427472–1427472. 3 indexed citations
3.
Berube, Bryan J., Brendan K. Podell, David F. Ackart, et al.. (2024). Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques. SHILAP Revista de lepidopterología. 2(1). 49–49.
4.
5.
Ackart, David F., et al.. (2023). Gliosis, misfolded protein aggregation, and neuronal loss in a guinea pig model of pulmonary tuberculosis. Frontiers in Neuroscience. 17. 1157652–1157652. 5 indexed citations
6.
Podell, Brendan K., Omowunmi Aibana, Chuan-Chin Huang, et al.. (2022). The Impact of Vitamin A Deficiency on Tuberculosis Progression. Clinical Infectious Diseases. 75(12). 2178–2185. 10 indexed citations
7.
Ackart, David F., et al.. (2020). Study of Real-Time Spatial and Temporal Behavior of Bacterial Biofilms Using 2-D Impedance Spectroscopy. IEEE Transactions on Biomedical Circuits and Systems. 14(5). 1051–1064. 5 indexed citations
8.
Ackart, David F., Megan Murray, Adam J. Chicco, et al.. (2020). Metformin enhances protection in guinea pigs chronically infected with Mycobacterium tuberculosis. Scientific Reports. 10(1). 16257–16257. 18 indexed citations
9.
Jeon, Albert B., Andrés Obregón‐Henao, David F. Ackart, et al.. (2017). 2-aminoimidazoles potentiate ß-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing ß-lactamase secretion and increasing cell envelope permeability. PLoS ONE. 12(7). e0180925–e0180925. 18 indexed citations
10.
Podell, Brendan K., et al.. (2017). A model of type 2 diabetes in the guinea pig using sequential diet-induced glucose intolerance and streptozotocin treatment. Disease Models & Mechanisms. 10(2). 151–162. 48 indexed citations
11.
Podell, Brendan K., et al.. (2015). Second generation 2-aminoimidazole based advanced glycation end product inhibitors and breakers. Bioorganic & Medicinal Chemistry Letters. 25(21). 4820–4823. 13 indexed citations
12.
Podell, Brendan K., et al.. (2015). Inhibition and breaking of advanced glycation end-products (AGEs) with bis-2-aminoimidazole derivatives. Tetrahedron Letters. 56(23). 3406–3409. 10 indexed citations
13.
Podell, Brendan K., David F. Ackart, Andrés Obregón‐Henao, et al.. (2014). Increased Severity of Tuberculosis in Guinea Pigs with Type 2 Diabetes. American Journal Of Pathology. 184(4). 1104–1118. 56 indexed citations
14.
Ackart, David F., Erick A. Lindsey, Brendan K. Podell, et al.. (2014). Reversal ofMycobacterium tuberculosisphenotypic drug resistance by 2-aminoimidazole-based small molecules. Pathogens and Disease. 70(3). 370–378. 36 indexed citations
15.
Podell, Brendan K., et al.. (2012). Non-Diabetic Hyperglycemia Exacerbates Disease Severity in Mycobacterium tuberculosis Infected Guinea Pigs. PLoS ONE. 7(10). e46824–e46824. 41 indexed citations
16.
Kato‐Maeda, Midori, Crystal A. Shanley, David F. Ackart, et al.. (2012). Beijing Sublineages of Mycobacterium tuberculosis Differ in Pathogenicity in the Guinea Pig. Clinical and Vaccine Immunology. 19(8). 1227–1237. 70 indexed citations
17.
Palanisamy, Gopinath S., Natalie M. Kirk, David F. Ackart, et al.. (2012). Uptake and Accumulation of Oxidized Low-Density Lipoprotein during Mycobacterium tuberculosis Infection in Guinea Pigs. PLoS ONE. 7(3). e34148–e34148. 43 indexed citations
18.
Shang, Shaobin, Diane Ordway, Marcela Henao‐Tamayo, et al.. (2011). Cigarette Smoke Increases Susceptibility to Tuberculosis—Evidence From In Vivo and In Vitro Models. The Journal of Infectious Diseases. 203(9). 1240–1248. 87 indexed citations
19.
Palanisamy, Gopinath S., Natalie M. Kirk, David F. Ackart, et al.. (2011). Evidence for Oxidative Stress and Defective Antioxidant Response in Guinea Pigs with Tuberculosis. PLoS ONE. 6(10). e26254–e26254. 101 indexed citations
20.
Shang, Shaobin, Crystal A. Shanley, Marcela Henao‐Tamayo, et al.. (2010). Activities of TMC207, Rifampin, and Pyrazinamide against Mycobacterium tuberculosis Infection in Guinea Pigs. Antimicrobial Agents and Chemotherapy. 55(1). 124–131. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rajiv L. Gaur Breakdown of academic impact, for papers by Santosh Kumar Breakdown of academic impact, for papers by Julia Roberts Breakdown of academic impact, for papers by Marie I. Samanovic Breakdown of academic impact, for papers by Mark J. Koenigsknecht Breakdown of academic impact, for papers by Zhongji Meng Breakdown of academic impact, for papers by Hua Gao Breakdown of academic impact, for papers by Josephine Ni Breakdown of academic impact, for papers by John Adamson Breakdown of academic impact, for papers by A Wildfeuer
Rankless by CCL
2026